Detailed Abstract
[E-poster]
[EP067] Clinicopathological Differences in T2 Gallbladder Cancer According to Tumor Location
Wan-Joon KIM1, Tae-Wan LIM2, Pyoung-Jae PARK2, Sae-Byeol CHOI1, Wan-Bae KIM*1
1Division of Hepatobiliary Pancreas Surgery, Department of Surgery, Korea University Guro Hospital, Korea University Medical College, Korea
2Division of Transplantation Vascular Surgery, Department of Surgery, Korea University Guro Hospital, Korea University Medical College, Korea
Introduction : We aimed to identify clinicopathological differences and factors affecting survival outcomes of stage T2a and T2b gallbladder cancer (GBC) and validate the oncological benefits of regional lymphadenectomy and hepatic resection in these patients.
Methods : This single-center study enrolled patients who were diagnosed with pathologically confirmed T2 GBC and underwent curative resection between January 1995 and December 2017. Eighty-two patients with T2a and 50 with T2b GBCs were identified, and clinical information was retrospectively collected from medical records and analyzed
Results : Three- and 5-year overall survival rates were 96.8% and 96.8% and 80.7% and 80.7% in T2a and T2b groups, respectively (p=0.007). Three- and 5-year survival rates among all T2 GBC patients without and with lymph node metastasis were 97.2% and 94.4% and 81.3% and 81.3%, respectively (p=0.029). There was no difference in survival rates between the two groups according to whether hepatic resection was performed (p=0.320). However, in the T2b group, those who underwent hepatic resection demonstrated a better survival rate than those who did not (p=0.029). Multivariate analysis revealed that lymph node metastasis, vascular invasion, tumor location, and adjuvant chemotherapy were significant independent prognostic factors.
Conclusions : Hepatic resection was not always necessary in patients with peritoneal-side GBC. Considering the clinicopathological features and recurrence patterns of hepatic-side GBC, a systematic treatment plan, including radical resection and adjuvant chemotherapy, should be established.
Methods : This single-center study enrolled patients who were diagnosed with pathologically confirmed T2 GBC and underwent curative resection between January 1995 and December 2017. Eighty-two patients with T2a and 50 with T2b GBCs were identified, and clinical information was retrospectively collected from medical records and analyzed
Results : Three- and 5-year overall survival rates were 96.8% and 96.8% and 80.7% and 80.7% in T2a and T2b groups, respectively (p=0.007). Three- and 5-year survival rates among all T2 GBC patients without and with lymph node metastasis were 97.2% and 94.4% and 81.3% and 81.3%, respectively (p=0.029). There was no difference in survival rates between the two groups according to whether hepatic resection was performed (p=0.320). However, in the T2b group, those who underwent hepatic resection demonstrated a better survival rate than those who did not (p=0.029). Multivariate analysis revealed that lymph node metastasis, vascular invasion, tumor location, and adjuvant chemotherapy were significant independent prognostic factors.
Conclusions : Hepatic resection was not always necessary in patients with peritoneal-side GBC. Considering the clinicopathological features and recurrence patterns of hepatic-side GBC, a systematic treatment plan, including radical resection and adjuvant chemotherapy, should be established.
SESSION
E-poster
E-Session 7/27 ~ 7/29 ALL DAY